United Therapeutics (UTHR) Asset Writedowns and Impairment (2017 - 2022)

United Therapeutics has disclosed Asset Writedowns and Impairment across 5 years of filings, most recently posting $4.2 million for Q4 2022.

• Asset Writedowns and Impairment for Q4 2022 came in at $4.2 million, up 104.46% year-over-year; the trailing twelve-month figure through Sep 2024 was $4.2 million (down 62.5% YoY), and the FY2025 annual result was $21.7 million, changed N/A from the prior year.
• Asset Writedowns and Impairment came in at $4.2 million for Q4 2022 at United Therapeutics, down from $7.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $107.3 million in Q1 2021 to a low of -$94.2 million in Q4 2021.
• The 4-year median for Asset Writedowns and Impairment is $1.9 million (2019), against an average of $2.2 million.
• Peak annual rise in Asset Writedowns and Impairment reached 1685.19% in 2021, while the deepest fall reached 1644.44% in 2021.
• United Therapeutics' Asset Writedowns and Impairment stood at -$8.4 million in 2019, then surged by 35.71% to -$5.4 million in 2020, then slumped by 1644.44% to -$94.2 million in 2021, then jumped by 104.46% to $4.2 million in 2022.
• The last three Asset Writedowns and Impairment figures came in at $4.2 million (Q4 2022), $7.0 million (Q3 2022), and -$94.2 million (Q4 2021), per Business Quant data.